Boehringer Ingelheim Vetmedica Inc. has recently launched Ultra Duramune, a new canine vaccine line with 50 percent less volume per dose. Ultra Duramune vaccines are manufactured with PureFil technology, which includes improved purification processes and tighter manufacturing profiles, resulting in more serial-to-serial consistency. In addition, PureFil technology is designed to reduce vaccine reactions associated with extraneous proteins and cellular debris. The vaccines feature the same efficacy as Duramune Max and will be available in core and non-core combinations. Plus, many are newly formulated to better align with current AAHA vaccine guidelines. More information is available at www.biviultraduramune.com and dvm360.com/ultraduramune.